MDY News 247.47 05/20/2014 05:12:54 SPDR S&P Midcap 400 (MDY

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
SPDR S&P Midcap 400 (MDY) 247.47 $MDY

Midcap SPDR Trust Series 1 Rises 1.50% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon May 12, 4:01PM CDT
Midcap SPDR Trust Series 1 (AMEX:MDY) traded in a range yesterday that spanned from a low of $247.40 to a high of $250.48. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $249.36 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Look for Shares of Midcap SPDR Trust Series 1 to Potentially Pullback after Yesterday's 1.50% Rise
Comtex SmarTrend(R) - Mon May 12, 4:00PM CDT
Midcap SPDR Trust Series 1 (AMEX:MDY) traded in a range yesterday that spanned from a low of $247.40 to a high of $250.48. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $249.36 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

'Sell In May,' Other Red Flags Dooming Stock Market
at Investor's Business Daily - Tue May 06, 6:02PM CDT
Investors have more than just seasonal weakness to worry about in May as a handful of other red flags are weighing on the market. A sell-off in higher-growth, more economically sensitive stocks in April -- mainly small caps and technology -- coupled...

Jobs Report Weighs Heavy on Dems, GOP for Midterms
at The Street - Fri May 02, 1:49PM CDT
The jobs report is already influencing the midterm elections.

Investors Should Take Calm From the Latest Fed Statement
at The Street - Thu May 01, 4:00AM CDT
Investors received calming news from the latest Federal Reserve statement.

Midcap SPDR Trust Series 1 Set to Possibly Rebound After Yesterday's Selloff of 1.19%
Comtex SmarTrend(R) - Fri Apr 25, 4:16PM CDT
Midcap SPDR Trust Series 1 (AMEX:MDY) traded in a range yesterday that spanned from a low of $244.69 to a high of $247.39. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $245.95 on volume of 1.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Watch for Midcap SPDR Trust Series 1 to Potentially Rebound After Falling 1.19% Yesterday
Comtex SmarTrend(R) - Fri Apr 25, 4:15PM CDT
Midcap SPDR Trust Series 1 (AMEX:MDY) traded in a range yesterday that spanned from a low of $244.69 to a high of $247.39. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $245.95 on volume of 1.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

SPDR S&P MIDCAP 400 ETF Experiences Big Outflow
ETFChannel.com - Fri Apr 25, 10:11AM CDT
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P MIDCAP 400 ETF where we have detected an approximate $43.4 million dollar outflow -- that's a 0.3%...

First Week of MDY December 20th Options Trading
DividendChannel.com - Tue Apr 22, 11:10AM CDT
Investors in SPDR S&P MidCap 400 ETF saw new options begin trading this week, for the December 20th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 242 days until...

Midcap SPDR Trust Series 1 Set to Possibly Pullback After Yesterday's Rally of 1.16%
Comtex SmarTrend(R) - Wed Apr 16, 4:45PM CDT
Midcap SPDR Trust Series 1 (AMEX:MDY) traded in a range yesterday that spanned from a low of $243.14 to a high of $245.34. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $243.06 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

SmarTrend Watching for Potential Pullback in Shares of Midcap SPDR Trust Series 1 After 1.16% Gain
Comtex SmarTrend(R) - Wed Apr 16, 4:44PM CDT
Midcap SPDR Trust Series 1 (AMEX:MDY) traded in a range yesterday that spanned from a low of $243.14 to a high of $245.34. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $243.06 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Noteworthy ETF Outflows: MDY, AMG, XEC, HSIC
ETFChannel.com - Wed Apr 16, 9:49AM CDT
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P MIDCAP 400 ETF where we have detected an approximate $375.9 million dollar outflow -- that's a 2.5%...

After Yesterday's Decline of 2.18%, Midcap SPDR Trust Series 1 Offers Investors Better Value
Comtex SmarTrend(R) - Thu Apr 10, 4:00PM CDT
Midcap SPDR Trust Series 1 (AMEX:MDY) traded in a range yesterday that spanned from a low of $242.18 to a high of $248.23. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $243.00 on volume of 1.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

SmarTrend Watching for Potential Rebound in Shares of Midcap SPDR Trust Series 1 After 1.53% Loss
Comtex SmarTrend(R) - Fri Apr 04, 3:50PM CDT
Midcap SPDR Trust Series 1 (AMEX:MDY) traded in a range yesterday that spanned from a low of $247.94 to a high of $254.48. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $250.93 on volume of 2.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Look for Shares of Midcap SPDR Trust Series 1 to Potentially Rebound after Yesterday's 1.53% Sell Off
Comtex SmarTrend(R) - Fri Apr 04, 3:50PM CDT
Midcap SPDR Trust Series 1 (AMEX:MDY) traded in a range yesterday that spanned from a low of $247.94 to a high of $254.48. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $250.93 on volume of 2.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Midcap SPDR Trust Series 1 Falls 1.31% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Wed Mar 26, 4:00PM CDT
Midcap SPDR Trust Series 1 (AMEX:MDY) traded in a range yesterday that spanned from a low of $246.13 to a high of $251.07. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $247.38 on volume of 1.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

After Yesterday's Decline of 1.31%, Midcap SPDR Trust Series 1 Offers Investors Better Value
Comtex SmarTrend(R) - Wed Mar 26, 3:59PM CDT
Midcap SPDR Trust Series 1 (AMEX:MDY) traded in a range yesterday that spanned from a low of $246.13 to a high of $251.07. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $247.38 on volume of 1.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

MDY, GMCR, HSIC, TRMB: Large Inflows Detected at ETF
ETFChannel.com - Fri Mar 21, 10:04AM CDT
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P MidCap 400 ETF where we have detected an approximate $94.4 million dollar inflow -- that's a 0.6% increase...
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 236

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 294

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
TCL's Display Future: AI Meets Screens at DTC 2026

Updated Category News Views 637

Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 296

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading
Fibocom LTE Modules Test Drive Satellite Connectivity

Updated Category News Views 153

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Continue Reading
ASTS Faces Class Action; Investors Beware of Pitfalls

Updated Category News Views 281

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 344

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 385

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 254

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 337

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
"blog__more"> More News Articles